FAIM
ICPT

Financial Advocates Investment Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Financial Advocates Investment Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,200
Closed -$273K – 550
2019
Q4 		$273K Buy
+2,200
New +$197K 0.03% 417

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Financial Advocates Investment Management's ICPT Position: Q1 2020 in Review

Financial Advocates Investment Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 2,200 shares — an estimated $273K sold.

Financial Advocates Investment Management first reported a position in ICPT in Q4 2019 and held it in 1 quarter. The position peaked at $273K in Q4 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

  • Financial Advocates Investment Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Financial Advocates Investment Management sold 2,200 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $273K.
  • Financial Advocates Investment Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Financial Advocates Investment Management's Intercept Pharmaceuticals, Inc. position peaked at $273K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Financial Advocates Investment Management's 13F filing for Q1 2020, filed 29 Apr 2020.